Bionomics Limited (BNOX)


0.00 (0.00%)
Symbol BNOX
Price $7.15
Beta 2.536
Volume Avg. 0.01M
Market Cap 53.758M
Shares () -
52 Week Range 5.3-22.0
1y Target Est -
DCF Unlevered BNOX DCF ->
DCF Levered BNOX LDCF ->
Operating Margin -
Debt / Equity 14.75% Neutral
P/E -3.31 Strong Sell
P/B -


Consensus EPS

Upgrades & Downgrades

NASDAQ Global Market

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.